Autologous Transplantation Using Donor Leukocytes Loaded
autologous stem cells transplantation (ASCT)
carrier cells
minimal residual disease (MRD)
multiple myeloma (MM)
myxoma virus (MYXV)
tumor micreoenvironment (TME)
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
25 Sep 2020
25 Sep 2020
Historique:
received:
27
05
2020
accepted:
19
06
2020
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
23
7
2020
Statut:
epublish
Résumé
Multiple myeloma (MM) is a hematological malignancy of monoclonal plasma cells that remains incurable. Standard treatments for MM include myeloablative regimens and autologous cell transplantation for eligible patients. A major challenge of these treatments is the relapse of the disease due to residual MM in niches that become refractory to treatments. Therefore, novel therapies are needed in order to eliminate minimal residual disease (MRD). Recently, our laboratory reported that virotherapy with oncolytic myxoma virus (MYXV) improved MM-free survival in an allogeneic transplant mouse model. In this study, we demonstrate the capacity of donor autologous murine leukocytes, pre-armed with MYXV, to eliminate MRD in a BALB/c MM model. We report that MYXV-armed bone marrow (BM) carrier leukocytes are therapeutically superior to MYXV-armed peripheral blood mononuclear cells (PBMCs) or free virus. Importantly, when cured survivor mice were re-challenged with fresh myeloma cells, they developed immunity to the same MM that had comprised MRD.
Identifiants
pubmed: 32695875
doi: 10.1016/j.omto.2020.06.011
pii: S2372-7705(20)30090-5
pmc: PMC7364119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
171-188Informations de copyright
© 2020 The Author(s).
Références
Vaccine. 2013 Sep 6;31(39):4252-8
pubmed: 23726825
Front Immunol. 2018 Apr 26;9:866
pubmed: 29755464
Blood. 2011 May 26;117(21):5573-81
pubmed: 21441462
Cancer Res. 2017 Apr 15;77(8):2052-2063
pubmed: 28143835
Expert Opin Biol Ther. 2007 Sep;7(9):1415-25
pubmed: 17727330
Cancer Gene Ther. 2010 Jul;17(7):476-83
pubmed: 20168350
Gene Ther. 2008 May;15(10):797-806
pubmed: 18356812
N Engl J Med. 2004 Oct 28;351(18):1860-73
pubmed: 15509819
Ther Adv Hematol. 2019 Nov 14;10:2040620719888111
pubmed: 31798820
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):1-7
pubmed: 31767529
Mol Ther Oncolytics. 2016 Dec 14;4:31-40
pubmed: 28345022
Cell Rep. 2016 Apr 12;15(2):264-73
pubmed: 27050526
Cancers (Basel). 2019 May 11;11(5):
pubmed: 31083559
J Virol. 2009 Aug;83(16):8108-21
pubmed: 19515783
Cancers (Basel). 2019 Dec 13;11(12):
pubmed: 31847174
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
Nat Rev Cancer. 2007 Aug;7(8):585-98
pubmed: 17646864
Mol Ther Oncolytics. 2016 Dec 07;3:16032
pubmed: 27933316
Cancer Lett. 2016 Feb 28;371(2):161-70
pubmed: 26655276
Br J Haematol. 2019 Sep;186(6):807-819
pubmed: 31364160
PLoS One. 2007 Oct 24;2(10):e1075
pubmed: 17957257
Mol Ther Oncolytics. 2019 Nov 29;16:41-52
pubmed: 31930165
Nat Rev Cancer. 2005 Apr;5(4):263-74
pubmed: 15776005
Blood. 2014 May 22;123(21):3305-15
pubmed: 24723682
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e30-e37
pubmed: 31780415
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):169-75
pubmed: 20211576
Adv Virol. 2012;2012:186512
pubmed: 22312362
Biol Blood Marrow Transplant. 2012 Oct;18(10):1540-51
pubmed: 22516053
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
Cancer Res. 2019 Sep 1;79(17):4503-4514
pubmed: 31289131
Immunotherapy. 2015;7(6):611-9
pubmed: 26098919
Int J Cancer. 2019 Oct 1;145(7):1958-1969
pubmed: 30972741
Neuro Oncol. 2016 Mar 8;18(8):1088-1098
pubmed: 26962017
Oncolytic Virother. 2018 Feb 23;7:1-12
pubmed: 29503813
Blood. 2015 Jun 11;125(24):3778-88
pubmed: 25904246
J Clin Med. 2020 Jan 08;9(1):
pubmed: 31936317
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Cancers (Basel). 2018 Jun 14;10(6):
pubmed: 29903988
Semin Oncol Nurs. 2017 Aug;33(3):225-236
pubmed: 28688533
Leukemia. 2009 Mar;23(3):435-41
pubmed: 19039321
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
Lancet Haematol. 2019 Dec;6(12):e600-e601
pubmed: 31624046
Nat Med. 2016 Dec;22(12):1411-1420
pubmed: 27841872
Expert Rev Anticancer Ther. 2019 Oct;19(10):889-898
pubmed: 31595807
Front Oncol. 2019 Aug 20;9:699
pubmed: 31482061
Biomedicines. 2017 Feb 10;5(1):
pubmed: 28536351
Mol Cancer Ther. 2019 Jan;18(1):127-138
pubmed: 30322950